Stromal CD73 Expression in Breast Cancer: Subtype-specific Expression and its Prognostic Significance.

IF 1.6 4区医学 Q4 ONCOLOGY Anticancer research Pub Date : 2024-08-01 DOI:10.21873/anticanres.17187

Masumi Tanaka, Mikiko Aoki, Yoshiko Masuda, Yasuteru Yoshinaga, Makoto Hamasaki, Akinori Iwasaki, Toshihiko Sato

{"title":"Stromal CD73 Expression in Breast Cancer: Subtype-specific Expression and its Prognostic Significance.","authors":"Masumi Tanaka, Mikiko Aoki, Yoshiko Masuda, Yasuteru Yoshinaga, Makoto Hamasaki, Akinori Iwasaki, Toshihiko Sato","doi":"10.21873/anticanres.17187","DOIUrl":null,"url":null,"abstract":"Background/aim: Invasive ductal carcinoma (IDC) is classified into distinct subtypes with varying prognoses and treatment sensitivities. For instance, triple-negative breast cancer (TNBC) is associated with poorer outcomes than other subtypes. We have previously reported the role of interstitial CD73 in tumor invasion and its correlation with prognosis in other cancers. This study aimed to investigate the expression of stromal CD73 (sCD73) in IDC and its potential prognostic significance.Patients and methods: We analyzed 61 cases of human epidermal growth factor receptor 2-negative IDC, including TNBC and hormone receptor-positive (luminal-type) cases, treated surgically at our institution from 2005 to 2010. Cases that received preoperative drug therapy were excluded. CD73 expression was evaluated by immunostaining of the tumor stroma.Results: sCD73 expression was observed in 70% of all cases, with a significantly higher rate in TNBC (93%) compared with luminal breast cancer (48%). High sCD73 expression was associated with poor prognosis in terms of overall survival (OS) and disease-free survival (DFS) across all cases. In patients with luminal breast cancer, high sCD73 expression was also indicative of poor prognosis with respect to both OS and DFS.Conclusion: High expression of sCD73 is associated with poor prognosis in IDC, particularly in luminal breast cancer. Further research is needed to establish sCD73 as an independent prognostic factor.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17187","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Invasive ductal carcinoma (IDC) is classified into distinct subtypes with varying prognoses and treatment sensitivities. For instance, triple-negative breast cancer (TNBC) is associated with poorer outcomes than other subtypes. We have previously reported the role of interstitial CD73 in tumor invasion and its correlation with prognosis in other cancers. This study aimed to investigate the expression of stromal CD73 (sCD73) in IDC and its potential prognostic significance.

Patients and methods: We analyzed 61 cases of human epidermal growth factor receptor 2-negative IDC, including TNBC and hormone receptor-positive (luminal-type) cases, treated surgically at our institution from 2005 to 2010. Cases that received preoperative drug therapy were excluded. CD73 expression was evaluated by immunostaining of the tumor stroma.

Results: sCD73 expression was observed in 70% of all cases, with a significantly higher rate in TNBC (93%) compared with luminal breast cancer (48%). High sCD73 expression was associated with poor prognosis in terms of overall survival (OS) and disease-free survival (DFS) across all cases. In patients with luminal breast cancer, high sCD73 expression was also indicative of poor prognosis with respect to both OS and DFS.

Conclusion: High expression of sCD73 is associated with poor prognosis in IDC, particularly in luminal breast cancer. Further research is needed to establish sCD73 as an independent prognostic factor.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

乳腺癌基质 CD73 表达：亚型特异性表达及其预后意义

背景/目的：浸润性导管癌（IDC）分为不同的亚型，其预后和治疗敏感性也各不相同。例如，与其他亚型相比，三阴性乳腺癌（TNBC）的预后较差。我们以前曾报道过间质 CD73 在肿瘤侵袭中的作用及其与其他癌症预后的相关性。本研究旨在探讨基质 CD73（sCD73）在 IDC 中的表达及其潜在的预后意义：我们分析了 2005 年至 2010 年在本院接受手术治疗的 61 例人表皮生长因子受体 2 阴性 IDC，包括 TNBC 和激素受体阳性（管腔型）病例。排除了术前接受药物治疗的病例。通过对肿瘤基质进行免疫染色来评估 CD73 的表达。结果：在所有病例中，有 70% 观察到了 sCD73 的表达，其中 TNBC（93%）的表达率明显高于管腔型乳腺癌（48%）。在所有病例中，sCD73的高表达与总生存期（OS）和无病生存期（DFS）的不良预后有关。在管腔型乳腺癌患者中，sCD73的高表达也表明OS和DFS的预后较差：结论：sCD73的高表达与IDC的不良预后有关，尤其是在管腔型乳腺癌中。要将 sCD73 确定为一个独立的预后因素，还需要进一步的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.